A total of 24 patients (14 ALL, 3 AML, 3 DLBCL, 3 Burkitt and 1 T-cell lymphoblastic lymphoma) was prophylaxed with at least one dose of liposomal cytarabine over an 8-year period from 2004 to 2012.
Cytarabine is a chemotherapy drug for treating acute leukemias such as acute myeloid leukemia. Doctors also use it for some lymphomas, including Hodgkin lymphoma. Healthcare professionals often ...
Cytarabine is an efficient anticancer agent for acute myelogenous leukemia, but with short plasma half-life and rapid deamination to its inactive metabolite. The aim of this study was to design and ...
We performed a phase I trial of intrathecal (IT) liposomal cytarabine (DepoCyt; Enzon Pharmaceuticals, Piscataway, NJ and SkyePharma Inc, San Diego, CA) to determine the maximum-tolerated dose, the ...
An executive with Jazz Pharmaceuticals said the ability to extend survival time in patients with secondary AML, and potentially offer them improved odds for transplant is an advance over traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results